🇺🇸 FDA
Patent

US 11702389

Piperidine derivatives as HDAC1/2 inhibitors

granted A61PA61P35/00A61P35/02

Quick answer

US patent 11702389 (Piperidine derivatives as HDAC1/2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regenacy Pharmaceuticals, Inc.
Grant date
Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00, A61P7/00